http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NZ-571727-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a19f736e9a12c3e9e1330a750d7f5038 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70 |
| filingDate | 2009-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_909dbdc3aa0e115c24da515ff1596299 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_84cf6e5b66f4a5d3c7a7117a79176857 |
| publicationDate | 2012-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | NZ-571727-A |
| titleOfInvention | Neutralizing antibodies associated with ABO blood groups using antigen-lipid constructs |
| abstract | Disclosed is the use of a synthetic antigen-lipid construct of the structure F-S1-S2-L in the manufacture of a preparation for neutralising one or more populations of circulating antibody in a subject mammal wherein: -F is the epitope of a carbohydrate antigen (glycotope) reactive with the one or more populations of circulating antibody; -S1-S2 is a spacer linking F to L selected to provide an antigen-lipid construct that is dispersible in water and preferentially partitions into plasma relative to naturally occurring glycolipids; and -L is a di-acyl or di-alkyl glycerophospholipid. Further disclosed is the use where the preparation is a medicament for administration to a human prior to transfusion or transplantation to mitigate the risk of a clinically significant reaction to a donor antigen. |
| priorityDate | 2009-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 60.